Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

Source
Original press release as distributed by PR Newswire, shown unedited.
Published

An expanded U.S. 510(k) extends the Hugo™ RAS system's reach into one of the fastest-growing areas of U.S. robotic surgery. 

GALWAY, Ireland, Nov. 17, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in general surgery procedures.

Medtronic Hugo(TM) RAS system

The clearance covers all upper abdominal general surgical procedures, including but not limited to cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection. Additionally, lower abdominal procedures of inguinal hernia and appendectomy were cleared. Combined, these procedures account for about 3.5 million surgeries annually in the U.S. — more than half of all soft-tissue procedures performed in the country each year.

This clearance extends the Hugo RAS system's reach into surgical specialties where Medtronic technologies in open and laparoscopic approaches have been used for more than a half century.

"For decades, Medtronic has partnered with general surgeons, and we're bringing that same commitment to robotic surgery for U.S. customers. Hugo expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients' needs across care settings," said Matt Anderson, senior vice president and president of Medtronic's Surgical business.

The Hugo RAS system is in clinical use at a growing number of health systems and hospitals across the U.S. Globally, Hugo RAS system procedure growth is running at more than two times the robotic surgery market and is on track to surpass 50,000 procedures by the end of the Medtronic fiscal year. General surgery also represents the highest growth for Hugo RAS system procedures outside the U.S., surpassing urology and gynecology.

For U.S. hospitals, the clearance of general surgery procedures expands the range of procedures that can be performed with the Hugo RAS system beyond urology. The system's modular design allows surgical teams flexibility to use only the robotic arms needed for a given procedure, positioning them for their surgical technique and patient's anatomy, while the open console connects the surgeon with the OR team and patient. Surgeons can also use trusted Medtronic technology in their robotic cases, including the LigaSure™ RAS Maryland instrument, which brings vessel-sealing technology used in more than 45 million open and laparoscopic procedures to the Hugo RAS system.

"As an academic health system serving communities across Chicago, our priority is to ensure patients have access to high-quality surgical care and treatment options that best meet their individual needs," said Dr. Francesco Bianco, UI Health surgeon, and professor of surgery at the University of Illinois College of Medicine. "Expanding our robotic-assisted surgical capabilities with the Hugo RAS system allows us to offer additional treatment options, while supporting our commitment to advancing surgical education and training the next generation of surgeons."

Medtronic brings robotics, instruments, data, and expertise together with the goal of making surgery more precise, predictable, and personalized — and more accessible to more patients around the world. Alongside the Hugo RAS system and its connected surgical ecosystem, the company's distribution of the Sentire™* surgical system in select markets outside the U.S., is rooted in that pursuit.

Learn more at medtronic.com/HugoSpecialties.

Medtronic is the sole authorized distributor of Cornerstone Robotic's Sentire™* surgical system outside of the United States. Medtronic, the Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owner. All other brands are trademarks of a Medtronic company.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777

Ingrid Goldberg
Investor Relations
+1-763-505-2696

Medtronic plc

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html

This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.

Not part of the release

AlphAI analysis

ByAlphAI AI DeskAI-generated

Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.

Decision brief

The 30-second read

$MDTBullishMed
01

Why it matters

By expanding the procedure categories (including cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, small bowel resection, inguinal hernia, and appendectomy), the clearance increases the system’s eligible use cases for US hospitals and may broaden demand from general surgeons beyond urology.

02

Market read

This is a company-specific regulatory milestone that can expand Hugo’s addressable market in the US general surgery segment.

03

What to watch

The article provides procedure counts and growth claims but no reimbursement, pricing, or sales guidance, so near-term financial impact may be limited until utilization data emerges.

Relevance 7/10Novelty 8/10Timing: today’s FDA clearance announcement

Background

The FDA clearance is an expanded U.S. 510(k) for Medtronic’s Hugo robotic-assisted surgery system, extending labeled use into upper and lower abdominal general surgery procedures.

Company-level read

Ticker impact

$MDTBullishHigh confidence
Context

Medtronic (MDT) says FDA cleared its Hugo robotic-assisted surgery system for specified general surgery procedures under an expanded 510(k).

Expected impact

Likely positive bias as investors price in incremental market access and utilization ramp for Hugo RAS in general surgery.

Evidence & confidence

The article is a first-disclosed regulatory clearance expanding indications, which directly affects commercial scope for the Hugo system.

Market effects

Supports the broader surgical robotics adoption narrative by adding labeled indications and potentially increasing procedure throughput for robotic platforms.

US-focused clearance can accelerate US hospital adoption and training for Hugo in general surgery.

May reinforce global growth expectations for Hugo RAS as the company highlights faster growth outside the US as well.

Counterpoint

Regulatory clearance does not guarantee near-term procedure uptake; adoption may be constrained by capital budgets, surgeon training, and competitive installed base.

Key entities

  • Medtronic plc

    Announced FDA clearance for expanded general surgery indications for its Hugo robotic-assisted surgery system.

  • FDA

    Cleared the expanded 510(k) for Hugo RAS system use in specified general surgery procedures.

  • Hugo™ robotic-assisted surgery (RAS) system

    Medtronic’s robotic-assisted surgery platform whose labeled indications were expanded via 510(k).